Abbott Lowers 2010 Guidance Due To U.S. Health Care Reform; Q1 Sales Rise 14.6%
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbott adjusted its previous 2010 earnings per share guidance by $0.07 to range from $4.13 to $4.18.
You may also be interested in...
Health Care Reform's Impact Reflected In Pharma's Q1 Results
President Obama had barely put his signature to the new health care reform law when its impact on biopharma became clear. With Lilly in the lead, a parade of companies posted first quarter financial results which underscored a key point for the industry: it is bearing costs of the new law immediately, but won't reap the benefits for several years
Health Care Reform's Impact Reflected In Pharma's Q1 Results
President Obama had barely put his signature to the new health care reform law when its impact on biopharma became clear. With Lilly in the lead, a parade of companies posted first quarter financial results which underscored a key point for the industry: it is bearing costs of the new law immediately, but won't reap the benefits for several years
Lilly Slashes Revenue Forecasts For 2010 And 2011 Due To Health Care Reform
The drug maker blames changes to various government programs for revenue that will drop by hundreds of millions of dollars.